肝硬化患者肌少症的评估与临床管理

韩芳; 韩涛; 梁静

doi:10.3969/j.issn.1001-5256.2019.04.041

肝硬化患者肌少症的评估与临床管理

DOI: 10.3969/j.issn.1001-5256.2019.04.041

天津市第三中心医院肝内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1245
- HTML全文浏览量: 11
- PDF下载量: 339
- 被引次数: 0
出版历程
- 出版日期: 2019-04-20

Assessment and clinical management of sarcopenia in patients with liver cirrhosis

Department of Hepatology, Tianjin Third Central Hospital

摘要

摘要: 随着肝硬化病情进展,患者身体成分组成发生显著变化,肌少症是肝硬化患者尤其是失代偿肝硬化常见的合并症之一。约30%～70%的肝硬化患者存在肌少症,严重影响患者生存期,其与肝性脑病的发生密切相关,并且可能增加患者的感染风险。肌少症、肌肉脂肪化可作为肝细胞癌的不良预后指标,增加肝癌复发风险。综述了肌少症的相关定义、与肝硬化的关系及其评估和临床管理相关研究进展。
- 肝硬化 /
- 肌疾病,萎缩性 /
- 肌,骨骼 /
- 综述
Abstract: As the disease progresses, there is a significant change in the body composition of patients with liver cirrhosis, and sarcopenia is one of the common complications in liver cirrhosis, especially in decompensated cirrhosis. About 30%-70% of patients with liver cirrhosis have sarcopenia, which greatly affects patients' survival and is closely associated with the development of hepatic encephalopathy. Sarcopenia may also increase the risk of infection. Sarcopenia and muscle fatty degeneration can be used as poor prognostic indicators of hepatocellular carcinoma and may increase the risk of recurrence of liver cancer. This article reviews the research advances in the definition of sarcopenia, the association of sarcopenia with liver cirrhosis, and assessment and clinical management of sarcopenia.
- liver cirrhosis /
- muscular disorders, atrophic /
- muscle, skeletal /
- review

HTML全文

参考文献(56)

[1]TANDON P, NEY M, IRWIN I, et al. Severe muscle depletion in patients on the liver transplant wait list:Its prevalence and independent prognostic value[J]. Liver Transpl, 2012, 18 (10) :1209-1216.

[2]MONTANO-LOZA AJ, MEZA-JUNCO J, PRADO CM, et al.Muscle wasting is associated with mortality in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2012, 10 (2) :166-173. e1.

[3]PERIYALWAR P, DASARATHY S. Malnutrition in cirrhosis:Contribution and consequences of sarcopenia on metabolic and clinical responses[J]. Clin Liver Dis, 2012, 16 (1) :95-131.

[4]ROSENBERG IH. Sarcopenia:Origins and clinical relevance[J]. J Nutr, 1997, 127 (5 Suppl) :990S-991S.

[5] CRUZ-JENTOFT AJ, BAEYENS JP, BAUER JM, et al. Sarcopenia:European consensus on definition and diagnosis:Report of the European Working Group on Sarcopenia in older people[J]. Age Ageing, 2010, 39 (4) :412-423.

[6]FIELDING RA, VELLAS B, EVANS WJ, et al. Sarcopenia:An undiagnosed condition in older adults. Current consensus definition:prevalence, etiology, and consequences. International working group on sarcopenia[J]. J Am Med Dir Assoc, 2011, 12 (4) :249-256.

[7]ALBERINO F, GATTA A, AMODIO P, et al. Nutrition and survival in patients with liver cirrhosis[J]. Nutrition, 2001, 17 (6) :445-450.

[8]CAMPILLO B, PAILLAUD E, UZAN I, et al. Value of body mass index in the detection of severe malnutrition:Influence of the pathology and changes in anthropometric parameters[J].Clin Nutr, 2004, 23 (4) :551-559.

[9]MERLI M, GIUSTO M, GENTILI F, et al. Nutritional status:Its influence on the outcome of patients undergoing liver transplantation[J]. Liver Int, 2010, 30 (2) :208-214.

[10]PENG S, PLANK LD, MCCALL JL, et al. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis:A comprehensive study[J]. Am J Clin Nutr, 2007, 85 (5) :1257-1266.

[11]MERLI M, GIUSTO M, LUCIDI C, et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy:Results of a prospective study[J]. Metab Brain Dis, 2013, 28 (2) :281-284.

[12]MERLI M, LUCIDI C, GIANNELLI V, et al. Cirrhotic patients are at risk for health care-associated bacterial infections[J].Clin Gastroenterol Hepatol, 2010, 8 (11) :979-985.

[13]HUISMAN EJ, TRIP EJ, SIERSEMA PD, et al. Protein energy malnutrition predicts complications in liver cirrhosis[J]. Eur J Gastroenterol Hepatol, 2011, 23 (11) :982-989.

[14]SHIRAKI M, NISHIGUCHI S, SAITO M, et al. Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007-2011[J]. Hepatol Res, 2013, 43 (2) :106-112.

[15]MONTANO-LOZA AJ, DUARTE-ROJO A, MEZA-JUNCO J, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis[J]. Clin Transl Gastroenterol, 2015, 6:e102.

[16]NARDELLI S, LATTANZI B, TORRISI S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J].Clin Gastroenterol Hepatol, 2017, 15 (6) :934-936.

[17]MONTANO-LOZA AJ, MEZA-JUNCO J, BARACOS VE, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation[J]. Liver Transpl, 2014, 20 (6) :640-648.

[18]MASUDA T, SHIRABE K, IKEGAMI T, et al. Sarcopenia is a prognostic factor in living donor liver transplantation[J]. Liver Transpl, 2014, 20 (4) :401-407.

[19]FUJIWARA N, NAKAGAWA H, KUDO Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma[J]. J Hepatol, 2015, 63 (1) :131-140.

[20]ITOH S, SHIRABE K, YOSHIZUMI T, et al. Skeletal muscle mass assessed by computed tomography correlates to muscle strength and physical performance at a liver-related hospital experience[J]. Hepatol Res, 2016, 46 (4) :292-297.

[21]GOODPASTER BH, KELLEY DE, THAETE FL, et al. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content[J]. J Appl Physiol (1985) , 2000, 89 (1) :104-110.

[22]SHEN W, PUNYANITYA M, WANG Z, et al. Total body skeletal muscle and adipose tissue volumes:Estimation from a single abdominal cross-sectional image[J]. J Appl Physiol (1985) , 2004, 97 (6) :2333-2338.

[23]WELLS CI, MCCALL JL, PLANK LD. Relationship between total body protein and cross-sectional skeletal muscle area in liver cirrhosis is influenced by overhydration[J]. Liver Transpl, 2019, 25 (1) :45-55.

[24]PRADO CM, LIEFFERS JR, MCCARGAR LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts:A population-based study[J]. Lancet Oncol, 2008, 9 (7) :629-635.

[25]CAREY EJ, LAI JC, WANG CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease[J]. Liver Transpl, 2017, 23 (5) :625-633.

[26]YOSHIZUMI T, SHIRABE K, NAKAGAWARA H, et al. Skeletal muscle area correlates with body surface area in healthy adults[J]. Hepatol Res, 2014, 44 (3) :313-318.

[27]PENG TC, WU LW, CHEN WL, et al. Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III) :The importance of sarcopenia definition[J]. Clin Nutr, 2017.[Epub ahead of print]

[28]TSIEN CD, MCCULLOUGH AJ, DASARATHY S. Late evening snack:Exploiting a period of anabolic opportunity in cirrhosis[J]. J Gastroenterol Hepatol, 2012, 27 (3) :430-441.

[29]THAPALIYA S, RUNKANA A, MCMULLEN MR, et al. Alcohol-induced autophagy contributes to loss in skeletal muscle mass[J]. Autophagy, 2014, 10 (4) :677-690.

[30]TSIEN C, DAVULURI G, SINGH D, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis[J]. Hepatology, 2015, 61 (6) :2018-2029.

[31]European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70 (1) :172-193.

[32]MONTANO-LOZA AJ. Clinical relevance of sarcopenia in patients with cirrhosis[J]. World J Gastroenterol, 2014, 20 (25) :8061-8071.

[33]ANAND AC. Nutrition and muscle in cirrhosis[J]. J Clin Exp Hepatol, 2017, 7 (4) :340-357.

[34]MANDERS RJ, LITTLE JP, FORBES SC, et al. Insulinotropic and muscle protein synthetic effects of branched-chain amino acids:Potential therapy for type 2 diabetes and sarcopenia[J]. Nutrients, 2012, 4 (11) :1664-1678.

[35]DASARATHY S, MERLI M. Sarcopenia from mechanism to diagnosis and treatment in liver disease[J]. J Hepatol, 2016, 65 (6) :1232-1244.

[36]DAVULURI G, KROKOWSKI D, GUAN BJ, et al. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis[J]. J Hepatol, 2016, 65 (5) :929-937.

[37]BORACK MS, VOLPI E. Efficacy and safety of leucine supplementation in the elderly[J]. J Nutr, 2016, 146 (12) :2625S-2629S.

[38]KITAJIMA Y, TAKAHASHI H, AKIYAMA T, et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis[J]. J Gastroenterol, 2018, 53 (3) :427-437.

[39]YOSHIMURA Y, BISE T, SHIMAZU S, et al. Effects of a leucine-enriched amino acid supplement on muscle mass, muscle strength, and physical function in post-stroke patients with sarcopenia:A randomized controlled trial[J]. Nutrition, 2018, 58:1-6.

[40]SMITH GI. The effects of dietary omega-3s on muscle composition and quality in older adults[J]. Curr Nutr Rep, 2016, 5 (2) :99-105.

[41]RODE A, FOURLANOS S, NICOLL A. Oral vitamin D replacement is effective in chronic liver disease[J]. Gastroenterol Clin Biol, 2010, 34 (11) :618-620.

[42]MALHAM M, JORGENSEN SP, OTT P, et al. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology[J]. World J Gastroenterol, 2011, 17 (7) :922-925.

[43]KITSON MT, ROBERTS SK. D-livering the message:The importance of vitamin D status in chronic liver disease[J]. J Hepatol, 2012, 57 (4) :897-909.

[44]de VITA F, LAURETANI F, BAUER J, et al. Relationship between vitamin D and inflammatory markers in older individuals[J]. Age (Dordr) , 2014, 36 (4) :9694.

[45]ROBINSON SM, REGINSTER JY, RIZZOLI R, et al. Does nutrition play a role in the prevention and management of sarcopenia?[J]. Clin Nutr, 2018, 37 (4) :1121-1132.

[46]POJEDNIC RM, CEGLIA L, OLSSON K, et al. Effects of 1, 25-dihydroxyvitamin D3 and vitamin D3 on the expression of the vitamin d receptor in human skeletal muscle cells[J]. Calcif Tissue Int, 2015, 96 (3) :256-263.

[47]DAVULURI G, ALLAWY A, THAPALIYA S, et al. Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress[J]. J Physiol, 2016, 594 (24) :7341-7360.

[48]KUMAR A, DAVULURI G, SILVA R, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis[J]. Hepatology, 2017, 65 (6) :2045-2058.

[49]BAAR K. Training for endurance and strength:lessons from cell signaling[J]. Med Sci Sports Exerc, 2006, 38 (11) :1939-1944.

[50]BERZIGOTTI A, ALBILLOS A, VILLANUEVA C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity:The Sport Diet study[J]. Hepatology, 2017, 65 (4) :1293-1305.

[51]DIETRICH R, BACHMANN C, LAUTERBURG BH. Exerciseinduced hyperammonemia in patients with compensated chronic liver disease[J]. Scand J Gastroenterol, 1990, 25 (4) :329-334.

[52]GARCIA-PAGAN JC, SANTOS C, BARBERA JA, et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension[J]. Gastroenterology, 1996, 111 (5) :1300-1306.

[53]HIRAOKA A, MICHITAKA K, KIGUCHI D, et al. Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis[J]. Eur J Gastroenterol Hepatol, 2017, 29 (12) :1416-1423.

[54]SINCLAIR M, GROSSMANN M, HOERMANN R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone:A randomised controlled trial[J]. J Hepatol, 2016, 65 (5) :906-913.

[55]NAGASUE N, YUKAYA H, CHANG YC, et al. Active uptake of testosterone by androgen receptors of hepatocellular carcinoma in humans[J]. Cancer, 1986, 57 (11) :2162-2167.

[56]OHARA M, OGAWA K, SUDA G, et al. L-Carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis[J]. Hepatol Commun, 2018, 2 (8) :906-918.

施引文献

资源附件(0)

访问统计